[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615926":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":29,"locations":34,"responsibleParty":49,"collaborators":52,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":17,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":17,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":37,"whyStopped":17,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Chongqing Medical University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"sequential combined AVS","EXPERIMENTAL","non-ACTH-stimulated followed by ACTH-stimulated AVS",[13],"Diagnostic Test: sequential combined AVS",{"label":15,"type":16,"description":15,"interventionNames":17},"non-ACTH-stimulated AVS","NO_INTERVENTION",null,{"label":19,"type":16,"description":19,"interventionNames":17},"ACTH-stimulated AVS",[21],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":17},"DIAGNOSTIC_TEST",[9],[25],{"name":26,"affiliation":27,"role":28},"Shumin Yang","the Chongqing Primary Aldosteronism Study (CONPASS) Group","STUDY_CHAIR",[30],{"name":26,"role":31,"phone":32,"phoneExt":17,"email":33},"CONTACT","+86 023-89011552","ysm@hospital.cqmu.edu.cn",[35],{"facility":36,"status":37,"city":38,"state":17,"zip":17,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The First Affilated Hospital of Chongqing Medical University","RECRUITING","Chongqing","China","CN",{"type":42,"coordinates":43},"Point",[44,45],106.55771,29.56026,{"lat":45,"lon":44},[48],{"name":26,"role":31,"phone":32,"phoneExt":17,"email":33},{"type":50,"investigatorFullName":26,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"SPONSOR_INVESTIGATOR","Primary investigator",[53,55,57],{"name":54,"class":6},"First Affiliated Hospital of Kunming Medical University",{"name":56,"class":6},"The First Affiliated Hospital of Nanchang University",{"name":58,"class":59},"The People's Hospital of Chuxiong Yi Autonomous Prefecture","UNKNOWN","100615926","sequential-combined-versus-single-strategy-adrenal-venous-sampling-for-primary-aldosteronismscope-100615926",false,"NCT07298954","Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism(SCOPE)","Sequential Combined Versus Single-Strategy Adrenal Venous Sampling for Primary Aldosteronism: A Multicenter, Randomized Trial","Inclusion Criteria:\n\n* Fully understand the study process, voluntarily agree to participate, and sign informed consent.\n* Diagnosed with primary aldosteronism. # Age 18-70 years with hypertension, any sex.\n\nExclusion Criteria:\n\n* Patients for whom AVS can be bypassed: Typical BPA (normal serum potassium and plasma aldosterone concentration (PAC) \\\u003C 110 pg\u002FmL, eligible for direct medical therapy); Typical UPA (PAC ≥ 200 pg\u002FmL, plasma renin concentration (PRC) ≤ 5 μIU\u002FmL, spontaneous hypokalemia, unilateral adrenal adenoma ≥ 1 cm with normal contralateral adrenal on CT or 68Ga-Pentixafor PET-CT indicating unilateral functional tumor, eligible for direct surgery);\n* Refusal of AVS or surgery, or contraindication to surgery.\n* Allergy to ACTH or contrast agents.\n* Combined with autonomous cortisol secretion (1 mg overnight dexamethasone suppression test cortisol ≥ 50 nmol\u002FL).\n* Early-onset hypertension (\\\u003C20 years) with hypokalemia and family history, suggestive of familial hyperaldosteronism or Liddle syndrome.\n* Imaging cannot exclude pheochromocytoma or adrenocortical carcinoma (nodule ≥ 4 cm, CT ≥ 20 HU, or MRI suggestive).\n* Active malignancy.\n* Previous adrenal surgery.\n* Chronic glucocorticoid use that cannot be discontinued.\n* Adrenal insufficiency requiring hormone replacement.\n* Pregnancy or breastfeeding; history of alcohol or substance abuse, or inability to cooperate due to psychiatric disorders.\n* NYHA class III-IV heart failure or hospitalization for worsening heart failure in the past 3 months, stroke or acute coronary syndrome in past 3 months, severe anemia (Hb \\\u003C 60 g\u002FL), severe liver or renal disease (ALT ≥ 3×upper limit; eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 or dialysis), systemic inflammatory response syndrome (SIRS), poorly controlled diabetes (FBG ≥ 13.3 mmol\u002FL), severe obesity (BMI ≥ 35 kg\u002Fm2), untreated aneurysm, or other conditions severely interfering with study participation.","ALL","18 Years","70 Years",{"count":71,"type":72},456,"ESTIMATED","INTERVENTIONAL",[75],"NA","This study is a prospective, multicenter, randomized clinical trial aimed to compare the impact of three AVS diagnostic strategies on the clinical outcomes of patients with primary aldosteronism. The strategies include sequential combined AVS (non-ACTH-stimulated followed by ACTH-stimulated AVS), non- ACTH-stimulated AVS alone, and ACTH-stimulated AVS alone. The findings of this study will provide critical evidence for the clinical practice standards of AVS.",[78],"Primary Aldosteronism",[78,80,9,81,19,82],"Adrenal venous sampling","non-ACTH-stimulated","complete biochemical remission rate","2025-12-22",{"date":85,"type":86},"2025-12-24","ACTUAL",{"date":88,"type":72},"2025-12-25",{"date":90,"type":72},"2028-12-31",{"name":26,"class":6},1]